The U.S. Food and Drug Administration is reviewing a new Parkinson’s disease drug called tavapadon that could give people with the disease more control over their movements. If approved, it would be ...

A novel, noninvasive brain stimulation approach—known as transcranial temporal interference stimulation (TIs)—may offer a new ...

Oral medications are often the first treatment for Parkinson’s disease. They work by increasing dopamine levels or mimicking dopamine’s effects, but symptom control may change over time. Infusion ...

Meta CEO Mark Zuckerberg backed-Cellular Intelligence has acquired Danish drugmaker Novo Nordisk's cell therapy candidate for ...

Monoclonal antibodies can block a key immune-related protein that drives the spread of brain cell damage in Parkinson's ...

Neuromodulation is an adjunct to medication for Parkinson’s symptom management, with growing interest in whether it could one ...

On a special episode (first released on May 29, 2025) of The Excerpt podcast: Parkinson’s is a disease that afflicts an estimated 90,000 Americans every year. Dr. Lorenz Studer and Dr. Viviane Tabar ...

Rebecca King Crews talks about how husband Terry first told her about a new FDA approval for focused ultrasound for treating ...

7NEWS cameras were inside the clinic to witness the moment Walter Grkovic became the first patient in Australia to receive ...

Every Drive Toward a Cure car rally is more than just a drive—it’s a journey fueled by passion, friendship, and a shared ...

Researchers estimate that 89% of people with Parkinson's disease (PD) have speech and voice disorders including disorders of laryngeal, respiratory and articulatory function. Despite the high ...

Parkinson’s disease affects more than 1.1 million people in the U.S., according to the Parkinson’s Foundation.